Abstract
Intra-tumour heterogeneity is a leading cause of treatment failure and disease progression in cancer. While genetic mutations have long been accepted as a primary mechanism of generating this heterogeneity, the role of phenotypic plasticity is becoming increasingly apparent as a driver of intra-tumour heterogeneity. Consequently, understanding the role of this plasticity in treatment resistance and failure is a key component of improving cancer therapy. We develop a mathematical model of stochastic phenotype switching that tracks the evolution of drug-sensitive and drug-tolerant subpopulations to clarify the role of phenotype switching on population growth rates and tumour persistence. By including cytotoxic therapy in the model, we show that, depending on the strategy of the drug-tolerant subpopulation, stochastic phenotype switching can lead to either transient or permanent drug resistance. We study the role of phenotypic heterogeneity in a drug-resistant, genetically homogeneous population of non-small cell lung cancer cells to derive a rational treatment schedule that drives population extinction and avoids competitive release of the drug-tolerant sub-population. This model-informed therapeutic schedule results in increased treatment efficacy when compared against periodic therapy, and, most importantly, sustained tumour decay without the development of resistance.
Funder
Natural Sciences and Engineering Research Council of Canada
National Institutes of Health
U.S. Department of Energy
natural sciences and engineering research council of canada
national cancer institute
Moffitt Center of Excellence for Evolutionary Therapy
Publisher
Public Library of Science (PLoS)
Subject
Computational Theory and Mathematics,Cellular and Molecular Neuroscience,Genetics,Molecular Biology,Ecology,Modeling and Simulation,Ecology, Evolution, Behavior and Systematics
Reference76 articles.
1. Evolutionary Determinants of Cancer;M Greaves;Cancer Discovery,2015
2. Turning ecology and evolution against cancer;KS Korolev;Nature Reviews Cancer,2014
3. Tumour heterogeneity and resistance to cancer therapies;I Dagogo-Jack;Nature Reviews Clinical Oncology,2018
4. Tumor heterogeneity: Causes and consequences;A Marusyk;Biochimica et Biophysica Acta (BBA)—Reviews on Cancer,2010
5. Adaptive Therapy;RA Gatenby;Cancer Research,2009
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献